CN111135114A - Eye cream composition for fading fine lines and preparation method thereof - Google Patents

Abstract

The invention discloses an eye cream composition for fading fine lines and a preparation method thereof; comprises an A phase which takes an emulsifier as a main component, a B phase which contains a humectant and water, a C phase which contains an emulsification-stabilizing agent of an oil phase and a D phase which contains functional components such as acetyl hexapeptide-8 and the like. When in preparation, the phase A is added into an emulsifying pot and stirred evenly; stirring and dissolving the phase B uniformly, pumping into an emulsifying pot, starting stirring at 50-80 rpm, and homogenizing; adding the phase C into an emulsifying pot in batches, and homogenizing until the material body in the emulsifying pot becomes semi-transparent cream-shaped appearance; beginning to cool, and continuously stirring at 30-50 rpm; when the temperature is reduced to below 40 ℃, adding the phase D, and continuously stirring at 30-50 rpm; and continuously cooling to 25-40 ℃, and discharging. The invention starts from the reason of the generation of eye wrinkles, adopts the technical components of targeted combination of the factors in the eye wrinkles, prevents the generation of the wrinkles from different wrinkle-removing angles and combines the moisturizing mechanism, and solves the problem of various lines on the eyes.

Description

Eye cream composition for fading fine lines and preparation method thereof

Technical Field

The invention belongs to the technical field of daily chemical industry, and particularly relates to an eye cream composition for fading fine wrinkles and a preparation method thereof.

Background

The eye skin is the thinnest skin of the human body and is the part which moves most frequently. Modern life style brings more harm and burden to eye skin, people increasingly use computers in work and life, and a large number of newspapers and video discs are mainly used for leisure time, so that eyes and skin around the eyes are in a tense state for a long time, and eye fatigue, dry eyes and skin microcirculation around the eyes are easy to cause. Meanwhile, the long-time use of the heater and the air conditioner easily causes the skin to lack of water, the thickness of the epidermis and the corium layer of the eye skin is only 0.55 mm, and the thickness of the epidermis and the corium layer of the eye skin is only one fourth of the thickness of the face skin, so that the problem of water shortage and dryness is more easily caused; frequent physical and chemical injuries caused by the use of color cosmetics such as eye shadow, eye liner and mascara and the removal of makeup used for eye makeup all make the eye skin of people more fragile and sensitive, so that a series of problems such as dark circles, fine lines, looseness and the like are more easily caused, and therefore, the selection of a proper eye care product is a necessary skin care procedure.

Most of the functional eye care products in the market exert the functions by adding active compounds, such as acetyl hexapeptide-8, tripeptide, tetrapeptide … and the like; such a single application is weak in efficacy, and cannot comprehensively improve the skin condition of the eyes by comprehensively improving the tissue structure of the skin of the eyes.

Disclosure of Invention

The invention aims to prevent the generation of wrinkles and fade wrinkles (dry lines, fine lines, smile lines and true wrinkles) from the reasons of the generation of eye wrinkles and from different wrinkle-removing angles by combining with a moisturizing mechanism; in particular to an eye cream composition for fading fine lines and a preparation method thereof, which solve the problem of various lines of eyes by adopting an internal cause targeting combination component of the eye wrinkles.

The purpose of the invention is realized by the following technical scheme:

the invention relates to an eye cream composition for fading fine lines, which comprises the following components in percentage by weight:

preferably, the dimethicone is a mixture of PMX-200Fluid (5cst), 9041Silicone elastomer blend and PMX-1403 Fluid.

Preferably, the simethicone comprises the following components in percentage by weight based on the total weight of the composition:

PMX-200Fluid(5cst) 0.50％～8.0％，

9041Silicone Elastomer Blend 1.0％～10.0％，

PMX-1403 Fluid 0.50％～5.0％。

preferably, the silicone O/W emulsifier is selected from

CARE XL 80。

Preferably, the stabilizing thickener is TEGO Carbomer 341 ER.

Preferably, the auxiliary humectant is selected from

68。

Preferably, the emulsification-stabilizing agent of the oil phase is SEPIPLUS 400.

Preferably, the low molecular weight hyaluronic acid silanol is EPIDERMOSIL SP.

Preferably, EXSY338Y324 is selected as the eye-closing agent.

The invention also relates to a preparation method of the eye cream composition for fading fine wrinkles, which comprises the following steps:

adding the phase A into an emulsifying pot, and uniformly stirring;

adding the phase B into a water phase pot, stirring and dissolving uniformly, pumping into an emulsifying pot, starting stirring at 50-80 rpm, and homogenizing until the material in the emulsifying pot is uniform;

adding the phase C into an emulsifying pot in batches, and homogenizing until the material body in the emulsifying pot becomes semi-permeable cream-shaped appearance; beginning to cool, and continuously stirring at 30-50 rpm;

when the temperature is reduced to below 40 ℃, adding the phase D, and continuously stirring at 30-50 rpm;

and continuously cooling to 25-40 ℃, and discharging.

Compared with the prior art, the invention has the following beneficial effects:

1. the eye cream is added with expression striation hexapeptide (acetyl hexapeptide-8), and the acting protein complex is the same as botulinum toxin A, so that the muscle contraction is adjusted; it has the effects of destabilizing the SNARE complex, reducing wrinkle formation, minimizing the depth, volume and length of existing wrinkles and expression lines, and minimizing skin roughness; after 7 days, the peptides were able to reduce the mean values of wrinkle volume and length by 20.6% and 15.9%, respectively, both statistically significant;

2. the eye cream of the invention is added with messenger factor-active peptide (Matrixyl) for reconstructing and repairing skin structure^TM3000) By reconstructing a fragile mastoid dermal network, the photoaging of skin is reduced, the new synthesis of extracellular matrix macromolecules is activated, and a visible anti-wrinkle effect is given to the product;

3. the eye cream of the invention is added with an optimized hyaluronic acid derivative (EPIDERMOSIL SP) which acts on each layer of skin to promote the skin to generate hyaluronic acid per se as if a finger is injected with a 'water light needle'; the unique molecule promotes the skin keratinocytes to express more CD44 receptors, promotes the generation of more hyaluronic acid, enhances the capacity of combining with the hyaluronic acid, and enters the virtuous cycle of endogenous generation of the hyaluronic acid; promoting the activity of fibroblasts, generating more collagen and effectively promoting the plumpness of the dermis.

4. In the eye cream of the invention, EPIDERMOSIL SP and acetyl hexapeptide-8, Matrixyl^TM3000 has synergistic effect, and has excellent effects of preventing wrinkle, and eliminating wrinkle (dry line, fine line, smile line, and true wrinkle).

Detailed Description

The present invention will be described in detail with reference to specific examples. The following examples will assist those skilled in the art in further understanding the invention, but are not intended to limit the invention in any way. It should be noted that variations and modifications can be made by persons skilled in the art without departing from the spirit of the invention. All falling within the scope of the present invention.

Eye cream composition of the present invention in the following examples, silicone O/W emulsifier is selected

CARE XL 80 comprising bis-PEG/PPG-20/5 PEG/PPG-20/5 polydimethylsiloxane, methoxy PEG/PPG-25/4 polydimethylsiloxane, caprylic/capric triglyceride;

the dimethyl Silicone oil is selected from PMX-200Fluid, 5cst (polydimethylsiloxane) 0.50-8.0%, 9041Silicone Elastomer Blend (polydimethylsiloxane and polydimethylsiloxane cross-linked polymer) 1.0-10.0%, PMX-1403Fluid (polydimethylsiloxane, dimethiconol) 0.50-5.0%;

the stable thickening agent is TEGO Carbomer 341ER (acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer);

glycerol polyether is selected

EG-1 glyceryl polyether-26;

1, 2-pentanediol

5；

Auxiliary humectant selection

68(1, 2-hexanediol, octaethylene glycol);

the emulsifying-stabilizing agent of the oil phase is SEPIPLUS 400 (polyacrylate-13, polyisobutylene, polysorbate-20);

acetyl hexapeptide-8 is selected

SOLUTIONC (water, acetyl hexapeptide-8, caprylyl glycol);

the low molecular weight hyaluronic acid silanol is EPIDERMOSIL SP (water, silanetriol, hyaluronic acid, methyl propylene glycol, citric acid);

Matrixyl^TM3000 comprises glycerol, water, butylene glycol, carbomer, polysorbate-20, palmitoyl tripeptide-1, palmitoyl tetrapeptide-7;

the phytosterol additive is selected from

(water, 1, 3-propanediol, phytosterols);

the herba Portulacae Extract is Portulaca Extract (water, butanediol, herba Portulacae Extract);

the eye surrounding agent is EXSY338Y 324; it comprises Capsicum FRUTESCENS (Capsicum FRUTESCENS) fruit extract, grapefruit (Citrus PARADISI) fruit extract, Ruscus ACULEATUS (Ruscus ACULEATUS) root extract, Equisetum arvense (Equisetum marvense) extract, Glycyrrhiza GLABRA (Glycyrrhiza GLABRA) root extract, ascorbyl methyl pectolanate, aminoethyl phosphinic acid, methylsilanol hydroxyprolinate aspartate, dimethylsilanol hyaluronate, PEG-35 castor oil, propylene glycol, butylene glycol, water;

use of date seed extract

1201 (glycerol, water, date seed, ascorbic acid (vitamin C)).

The specific formula and the preparation method are shown in the following examples:

examples 1 to 4

The embodiments 1 to 4 relate to an eye cream for reducing fine wrinkles, which comprises the following components by weight percentage based on the total weight of the composition:

the preparation method comprises the following specific steps:

adding the phase A into an emulsifying pot, and uniformly stirring for later use;

adding the phase B into a water phase pot, stirring and dissolving uniformly, and setting the temperature to be 80 ℃ for later use;

observing and determining that the phase A is completely and uniformly stirred in the emulsifying pot; the phase B is completely stirred and dissolved uniformly in a water phase pot without particles;

and pumping the B item into an emulsifying pot, starting stirring at 50-80 rpm, homogenizing at 3000rpm, and observing whether the material body is uniform or not within 3 minutes.

When the material in the emulsifying pot is uniform, adding the C items in three times, and homogenizing at 3000rpm for 3 minutes each time. Until the material body in the emulsifying pot becomes fine and smooth semi-transparent cream-shaped appearance, then starting cooling water to start cooling, and continuously stirring at 40 rpm;

when the temperature is reduced to below 40 ℃, sequentially adding the phase D, and continuously stirring at 40rpm for 10 mins;

and continuously cooling to about 35 ℃, discharging, measuring various indexes, and filling into a container after the indexes are qualified.

The technical parameters of the prepared eye cream are as follows:

appearance: the white-off-white color is uniform and fine cream,

odor: the odor of the product is consistent with that of a standard sample,

heat resistance: the test is stable at 45 ℃ for 3 months,

cold resistance: stability was tested at-12 ℃ for 3 months.

Example 5 application

Skin safety evaluation was performed on the eye creams prepared in the above examples and comparative examples:

30 persons, 15 men and 15 women, were selected for trial according to the subject inclusion criteria, with an average age of 40 years. The eye cream is put into a spot tester, and the dosage is about 0.020g to 0.025 g. The control hole is blank (no substance is placed), and the spot tester with eye cream is applied to the back of the subject with non-irritating adhesive tape, and is applied to the skin with palm gently for 24 h. And (3) after the spot tester is removed for 30min, observing skin reaction after the indentation disappears, and grading adverse reaction according to a skin adverse reaction grading standard table. If the result is negative, the test is observed once more at 24h and 48h after the patch test. The test result is no stimulation; therefore, the above eye cream is safe to the skin.

The human body test for evaluating the moisturizing effect is a commonly used moisturizing and anti-wrinkle effect evaluation method with high recognition degree. Therefore, the present example uses a human body test to evaluate the moisturizing and anti-wrinkle effects. The specific test process is as follows:

evaluation of moisturizing effect:

1) selecting a position 5cm away from the base of the palm on the inner sides of the left and right arms of the subject, and defining 3 areas (3cm multiplied by 3cm) with the same area on the left forearm as a test area; the same position of the right forearm was used as a blank control area and the corresponding areas of the left and right arms were tested simultaneously.

2) The subject applied the eye cream of the present invention, the eye cream of comparative example 1, and the eye cream commercially available in the general market to three test areas of the arm, respectively. The sample size was 20 microliters. The hydration state of the skin was measured 1,2, 4, 6, 8h after application using a skin moisture meter Corneometer CM825 (Courage Khazaka, Germany) and the water dispersion of the skin was measured 5 times using a transdermal moisture dispersion meter TewameterTM300 (Courage Khazaka, Germany) and averaged.

The test site cannot be smeared, wiped and cleaned with any substance. All measurements were carried out in a laboratory at room temperature 18-22 ℃ and relative humidity 40-60%. The subject must not leave the laboratory environment during the test.

And (3) evaluating the anti-wrinkle effect:

1. the eye cream of the invention is applied to half of the face of 24 female volunteers aged 35-45 years (especially to the crow's feet), and the eye cream of comparative example 1 is applied to the other half of the face, 2 times a day for 7 consecutive days. Measurements (wrinkle volume and depth) were made using the FOITS technique after the treatment started and ended, and then photographs were taken and the skin morphology was quantitatively evaluated.

2. 18 female volunteers aged 35-55 were applied with the eye cream of the present invention on half of the face (including the crow's feet) and the eye cream of comparative example 1 on the other half of the face 2 times a day for 28 consecutive days. Skin was replica sampled before and after use and analyzed using PRIMOS technique. The face was photographed and examined closely.

The test results were as follows:

1. the eye cream sold on the market has no obvious change in the aspect of skin moisture content compared with that before use; the eye cream of the comparative example is slightly superior to the commercial eye cream in increasing the skin moisture content; the eye cream is obviously superior to the eye creams sold on the market and the eye creams of the comparative examples in the aspects of improving the moisture content of the skin and effectively improving the fine wrinkles caused by dryness.

2. The eye cream of the comparative example has no obvious change in the aspects of improving the depth and volume of eye wrinkles; the eye cream can effectively improve expression lines on eyes after being used for 7 days; the real wrinkles of the eyes are obviously improved in 1 month.

3. The eye cream can make eye skin more elastic. The eye cream increases the transparent feeling of eye skin by promoting the skin optical effect formed by the close and ordered arrangement of cells; by promoting the synthesis of matrix among basal layer cells, the skin basal layer is more full and elastic. The eye cream of the comparative example has no obvious effect on increasing skin elasticity and skin permeability due to the limitation of the efficacy of the raw materials.

The foregoing description of specific embodiments of the present invention has been presented. It is to be understood that the present invention is not limited to the specific embodiments described above, and that various changes and modifications may be made by one skilled in the art within the scope of the appended claims without departing from the spirit of the invention.

Claims (10)

1. The eye cream composition for fading fine lines is characterized by comprising the following components in percentage by weight based on the total weight:

2. the fine line attenuating eye cream composition of claim 1, wherein the dimethicone is a mixture of PMX-200Fluid (5cst), 9041Silicone Elastomer Blend and PMX-1403 Fluid.

3. The fine line reduction eye cream composition according to claim 1, wherein the dimethicone comprises, in weight percent based on the total weight of the composition:

PMX-200Fluid(5cst) 0.50％～8.0％，

9041Silicone Elastomer Blend 1.0％～10.0％，

PMX-1403Fluid 0.50％～5.0％。

4. the fine line reducing eye cream composition according to claim 1, wherein the silicone O/W emulsifier is selected from the group consisting of

CARE XL 80。

5. The fine line reduction eye cream composition of claim 1, wherein the stabilizing thickener is tegocarmer 341 ER.

6. The fine line reducing eye cream composition of claim 1, wherein the adjunct moisturizer is selected from the group consisting of

68。

7. The fine line reduction eye cream composition according to claim 1, wherein the emulsion-stabilizer of the oil phase is SEPIPLUS 400.

8. The fine line attenuating eye cream composition of claim 1 wherein the low molecular weight hyaluronic acid silanol is EPIDERMOSIL SP.

9. The fine line reducing eye cream composition as claimed in claim 1, wherein the eye surrounding agent is EXSY338Y 324.

10. A method of preparing a fine line reducing eye cream composition according to claim 1, comprising the steps of:

adding the phase A into an emulsifying pot, and uniformly stirring;

adding the phase B into a water phase pot, stirring and dissolving uniformly, pumping into an emulsifying pot, starting stirring at 50-80 rpm, and homogenizing until the material in the emulsifying pot is uniform;

adding the phase C into an emulsifying pot in batches, and homogenizing until the material body in the emulsifying pot becomes semi-permeable cream-shaped appearance; beginning to cool, and continuously stirring at 30-50 rpm;

when the temperature is reduced to below 40 ℃, adding the phase D, and continuously stirring at 30-50 rpm;

and continuously cooling to 25-40 ℃, and discharging.